11月12日，中关村（000931.SZ）在互动易平台回复投资者关于高管持股的提问时表示，公司管理层于 2015年7月、2018年6月及2024年2月多次增持公司股票，距首次买入已超过十年从未减持，充分传递出 管理层对公司未来发展的信心和长期投资价值的认可。 这种长期持股的行为源自管理层坚守的长期发展主义，与中关村近年来稳健增长的业绩表现相得益彰。 2015年，公司确立了以"医药大健康产业"为核心的发展战略，近十年来医药业务收入比重持续提升； 2021年进一步聚焦医药主业，致力于构建"创新型医药产业集团"；2024年7月，公司再度优化战略定 位，明确"致力于成为领先的医药大健康产业服务商"的发展战略。近几年来，一方面"元治""博苏"等优 势领域药品销售业绩稳步提升，另一方面围绕精麻领域，羟考酮系列产品加速放量，哌甲酯等药品研发 将陆续"上线"，公司不仅实现了业绩的良好表现，更吸引了越来越多机构的关注，机构调研频频，充分 彰显出企业的价值前景。 从"医药大健康产业"为核心，到"致力于成为领先的医药大健康产业服务商"的战略定位，中关村正构建 起兼顾医药创新与大健康的多元化发展路径。管理层长期持股不减持，更彰显了对 ...

Product Overview - The company focuses on key narcotic products, including the oxycodone series and the new drug dihydroetorphine sublingual tablets, with a comprehensive product cluster in the analgesic field [3] - The core products include oxycodone raw materials and formulations, as well as tramadol series products from subsidiary companies [3] Sales Growth and Market Potential - The sales revenue of oxycodone injection is expected to exceed 100% growth in 2025, driven by increasing market demand in various medical fields [4] - The domestic sales of oxycodone products reached CNY 1.907 billion in 2024, with the company aiming to capture a significant market share [5] R&D Progress and Future Plans - The company is developing methylphenidate products, with the chewable tablets and oral suspension currently in the development stage [6] - A collaboration with a military research institute aims to enhance the R&D capabilities for methylphenidate products [6] - The market for methylphenidate is promising, with a projected sales revenue of CNY 526 million in 2024 [7] Strategic Product Pipeline - The company is expanding its narcotic product line, with several products in different stages of development, including oxycodone sustained-release tablets [8] - The strategic layout includes a focus on chronic disease management, narcotic specialties, and mental health products [9] Market Trends and Challenges - The demand for antihypertensive drugs is expected to grow due to an aging population and younger patients with hypertension [10] - The potential for the company's flagship product, Yuanzhi, to be included in national drug procurement policies is acknowledged, with strategies in place to mitigate impacts [10]